Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma

Since multiple myeloma (MM) is still not-curable, the management of relapse remains challenging. Given the known efficacy of alkylating agents in MM, we conducted a phase I/II study to test a new three drug combination in which Fotemustine (Muphoran), an alkylating agent of nitrosurea family, was ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Mangiacavalli, Silvia, Pochintesta, Lara, Pascutto, Cristiana, Cocito, Federica, Cazzola, Mario, Corso, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563219/
https://www.ncbi.nlm.nih.gov/pubmed/23224960
http://dx.doi.org/10.1002/ajh.23358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563219/
https://www.ncbi.nlm.nih.gov/pubmed/23224960
http://dx.doi.org/10.1002/ajh.23358

Ejemplares similares